How should Duphaston (dydrogesterone) be dosed for luteal‑phase support or menstrual disorders, and what are its contraindications and common side effects?

Duphaston (Dydrogesterone) Dosing and Clinical Use

For luteal phase support in hormone replacement therapy or menstrual disorders, dydrogesterone should be dosed at 10 mg twice daily (20 mg total) for 12-14 days per cycle when used sequentially, or 5 mg daily for continuous regimens.

Dosing Regimens

Sequential (Cyclic) Regimens

• Standard dose: 10 mg dydrogesterone for 12-14 days per month (typically days 14-25 or 16-25 of cycle) 1
• This regimen induces withdrawal bleeding and is appropriate when menstruation is acceptable to the patient
• Used in combination with continuous estradiol (transdermal or oral 1-2 mg daily)

Continuous Regimens

• Minimum dose: 5 mg dydrogesterone daily without interruption 1
• This regimen avoids withdrawal bleeding
• Typically combined with continuous 17β-estradiol (1-2 mg oral or transdermal patches)
• Example formulation: tablets containing 1-2 mg 17β-estradiol + 5 mg dydrogesterone administered continuously 1

Dysmenorrhea Treatment

• Dose: 10 mg twice daily (20 mg total) for 21 days from day 5-25 of cycle 2, 3
• Significant symptom improvement typically occurs after 2 cycles
• Can be continued for multiple cycles with good tolerability

Luteal Phase Support in IVF

• Dose: 10 mg three times daily (30 mg total) starting from oocyte retrieval 4, 5, 6
• Continue until pregnancy test or, if pregnant, until week 10
• Comparable efficacy to vaginal progesterone with better patient satisfaction

Clinical Context and Positioning

Micronized progesterone (MP) is the first-choice progestin due to lower cardiovascular and thrombotic risk 1. However, dydrogesterone serves as a second-line alternative when MP is unavailable, not tolerated, or patient preference favors oral administration 1.

The 2021 Blood Reviews guidelines specifically rank progestins as: MP first choice, then MPA, dydrogesterone, or norethisterone as second choices 1.

Key Advantages of Dydrogesterone

• Oral administration with high patient satisfaction and compliance 4, 5
• No interference with sexual activity (unlike vaginal preparations)
• Maintains ovulatory function in many patients 2, 3
• Minimal androgenic effects, making it suitable for patients with hypoandrogenism 1

Contraindications

While the provided evidence does not detail specific contraindications for dydrogesterone, standard progestin contraindications apply:

• Active thromboembolism or history of hormone-related thrombotic events
• Known or suspected breast cancer or other hormone-sensitive malignancies
• Active liver disease
• Undiagnosed vaginal bleeding
• Known hypersensitivity to dydrogesterone

Important caveat: The 2021 guidelines emphasize systematic risk-benefit analysis before prescribing any hormonal therapy, particularly in cancer survivors with higher baseline cardiovascular risk 1.

Common Side Effects

Most Frequent Adverse Events

• Breakthrough bleeding/metrorrhagia: Most common side effect (31.8% incidence in dysmenorrhea study) 2
• Headache and dizziness: Occur more frequently with dydrogesterone than vaginal progesterone 7
• Gastrointestinal symptoms: Abdominal pain, flatulence, nausea 7

Less Common Effects

• Mood changes, fatigue, weakness
• Breast tenderness
• Weight changes
• Premenstrual-tension-like symptoms (mood swings, bloating, fluid retention) 8

Reassuring safety data: 60-year post-approval surveillance shows favorable safety profile with minimal breast cancer risk, endometrial cancer risk, venous thromboembolism risk, and cardiovascular risk when used ≤260 weeks 7. No maternal complications or congenital anomalies linked to dydrogesterone use during pregnancy 7.

Practical Considerations

Monitoring

• Withdrawal bleeding patterns (in sequential regimens)
• Symptom relief for dysmenorrhea (VAS scores)
• Endometrial thickness if breakthrough bleeding occurs
• Pregnancy testing if withdrawal bleeding absent in sequential regimens

Duration of Treatment

• Hormone replacement: Continue until average age of natural menopause (45-55 years) 1
• Dysmenorrhea: Typically 3-12 cycles, with most patients experiencing relief after 2 cycles 2, 9
• Endometriosis: Long-term treatment (12+ cycles) shows sustained efficacy with >80% of patients having reduced or stable lesions 9

Common Pitfall

Do not assume dydrogesterone prevents ovulation—approximately 50-70% of patients maintain biphasic basal body temperature patterns indicating ovulatory cycles 2. Counsel patients about potential for pregnancy if contraception is not desired.